There are a plethora of immune-based biomarkers that can be harvested from patient specimens using different sample formats and analytical techniques. How to apply these biomarkers to patient populations in the context of drug discovery and clinical trials is an ongoing area of debate. To that end, how can we use immune biomarker strategies to optimize drug development and improve patient outcomes?

• Background – How are immune biomarkers currently used to shape clinical decisions and drug development?
• Landscape – What technologies are widely implemented in biomarker
• Novel approaches – How can we leverage new and emerging technologies and bespoke multi-omic signatures to maximize utility for a particular indication?
• Implementation – What are the minimum standards for analytical and clinical validation and regulatory hurdles for implementation?